Whalesbook
📉 The Financial Deep Dive
The Numbers:
Tilaknagar Industries Ltd. announced its Q3 FY26 results, showcasing a dramatic top-line expansion. Net Revenue surged by 95.0% YoY to ₹664 Cr (vs ₹340 Cr in Q3 FY25), primarily fueled by the acquisition of the Imperial Blue (IB) business which contributed 17.9 lac cases in its first month. Total volume climbed 76.1% YoY to 53.1 lac cases. Consolidated EBITDA also saw robust growth, up 82.3% YoY to ₹110 Cr, although the EBITDA margin compressed slightly to 16.6% from 17.7% in the prior year.
However, the bottom line presented a stark contrast. The company reported a Net Loss After Tax (PAT) of ₹(105) Cr for Q3 FY26, a significant downturn from a profit of ₹54 Cr in Q3 FY25. This was heavily impacted by Exceptional Items totalling ₹(169) Cr, largely comprising transaction costs (₹116 Cr), hedging costs (₹30 Cr), and TSSA/TSMA costs (₹22 Cr) related to the Imperial Blue acquisition.
Excluding these exceptional items, PAT showed a positive trend, growing 18.7% YoY to ₹64 Cr. The PAT margin, excluding exceptional items, stood at 9.5%, down from 15.7% in Q3 FY25, indicating pressure on profitability even after accounting for one-offs.
On a nine-month basis (9M FY26), revenue grew 43.1% YoY to ₹1,471 Cr, EBITDA increased 50.0% YoY to ₹265 Cr (margin at 18.0%), but PAT fell 76.5% YoY to ₹36 Cr. Excluding exceptional items, 9M PAT grew 34.8% YoY to ₹205 Cr (margin 13.8%).
The Quality:
The substantial net loss in Q3 FY26 overshadows the revenue growth, highlighting the significant financial costs associated with the Imperial Blue acquisition. While operating performance (EBITDA) improved, the reported net profit was dragged down by acquisition-related expenses. The balance sheet reflects this shift, with Gross Debt soaring from ₹47 Cr in September 2025 to ₹2,148 Cr in December 2025, and Net Debt turning from a net cash position of ₹(1,086) Cr to ₹1,526 Cr. This leverage is a key factor going forward.
The Grill:
Management commentary points towards a strategic transformation, aiming to restore IB to category leadership and expand margins by 150-250 bps over 24-36 months. They emphasized premiumisation, new product launches (Monarch Legacy Edition, Seven Islands), and increasing their stake in craft spirits (Spaceman Spirits Lab). The integration of IB is pitched as a value unlock through revenue and cost synergies. However, the immediate financial report shows a substantial short-term cost. Investors will be scrutinizing execution on margin expansion and deleveraging.
🚩 Risks & Outlook
The primary risk is the significant increase in leverage post-acquisition, with a large term loan having a balloon repayment structure starting in FY29. Managing this debt while executing the growth strategy will be critical. Margin pressure, although expected to ease, needs careful monitoring. The company's ability to successfully integrate IB, drive premiumisation, and achieve stated margin expansion targets will determine its future trajectory. The outlook is cautiously optimistic, banking on scale, distribution synergies, and a focused premiumisation strategy to overcome the immediate financial headwinds.